Sec Form 3 Filing - Khosla Rachna @ AMGEN INC - 2021-09-13

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Khosla Rachna 2. Issuer Name and Ticker or Trading Symbol AMGEN INC [ AMGN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) SVP, Business Development (Last) (First) (Middle) ONE AMGEN CENTER DRIVE 3. Date of Earliest Transaction (MM/DD/YY) 09/13/2021 (Street) THOUSAND OAKS, CA91320 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 4,068 ( 1 ) ( 2 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Nqso (Right to Buy) $ 162.6 05/01/2019( 3 ) 05/01/2027 Common Stock 1,252 D Nqso (Right to Buy) $ 177.46 04/27/2020( 4 ) 04/27/2028 Common Stock 1,518 D Nqso (Right to Buy) $ 177.31 05/03/2021( 5 ) 05/03/2029 Common Stock 3,642 D Nqso (Right to Buy) $ 236.36 05/05/2022( 6 ) 05/05/2030 Common Stock 2,515 D Nqso (Right to Buy) $ 239.64 04/30/2023( 7 ) 04/30/2031 Common Stock 3,260 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Khosla Rachna ONE AMGEN CENTER DRIVE THOUSAND OAKS, CA91320 SVP, Business Development Signatures /s/ Rachna Khosla 09/13/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )These shares include the following Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Equity Incentive Plan: 67 RSUs which will vest on 4/27/2022; 554 RSUs which will vest on 7/31/2022; 280 RSUs which vest in installments of 138 on 5/3/2022 and 142 on 5/3/2023; 300 RSUs which vest in two installments of 99 on 5/5/2022 and 5/5/2023 and one installment of 102 on 5/5/2024; and 375 RSUs which vest in installments of 123 on 4/30/2023, 124 on 4/30/2024 and 128 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. ( 2 )These shares include 90 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. ( 3 )1,252 of these non-qualified stock options have vested and are exercisable. ( 4 )1,001 of these non-qualified stock options have vested and are exercisable and 517 of these options will vest and become exercisable on 4/27/2022. ( 5 )1,201 of these non-qualified stock options have vested and are exercisable and the remaining options will vest and become exercisable in installments of 1,202 on 5/3/2022 and 1,239 on 5/3/2023. ( 6 )These non-qualified stock options will vest and become exercisable in three installments of 829 on 5/5/2022, 830 on 5/5/2023 and 856 on 5/5/2024. ( 7 )These non-qualified stock options will vest and become exercisable in three installments of 1,075 on 4/30/2023, 1,076 on 4/30/2024 and 1,109 on 4/30/2025.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.